Ambrx Biopharma (NASDAQ:AMAM) delivers shareholders stellar 119% return over 1 year, surging 4.5% in the last week alone

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right stock, you can make a lot more than 100%. For example, the Ambrx Biopharma Inc. (NASDAQ:AMAM) share price has soared 119% in the last 1 year. Most would be very happy with that, especially in just one year! Better yet, the 460% gain over the last thirty days has shareholders excited. We'll need to follow Ambrx Biopharma for a while to get a better sense of its share price trend, since it hasn't been listed for particularly long.

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

View our latest analysis for Ambrx Biopharma

Ambrx Biopharma wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Ambrx Biopharma actually shrunk its revenue over the last year, with a reduction of 58%. So we would not have expected the share price to rise 119%. It just goes to show the market doesn't always pay attention to the reported numbers. Of course, it could be that the market expected this revenue drop.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

Take a more thorough look at Ambrx Biopharma's financial health with this free report on its balance sheet.

A Different Perspective

Ambrx Biopharma shareholders should be happy with the total gain of 119% over the last twelve months. And the share price momentum remains respectable, with a gain of 327% in the last three months. This suggests the company is continuing to win over new investors. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 3 warning signs for Ambrx Biopharma you should be aware of, and 2 of them shouldn't be ignored.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

What are the risks and opportunities for Ambrx Biopharma?

NasdaqGS:AMAM

Ambrx Biopharma

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform.Show more

View Full Analysis

Rewards

• Revenue is forecast to grow 13.21% per year

Risks

• Highly volatile share price over the past 3 months

• Shareholders have been substantially diluted in the past year

• Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report

Further research on
Ambrx Biopharma

ValuationFinancial HealthInsider TradingManagement Team

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.